Takeda CEO-elect reports 324,729 ADS holdings

Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares.

Accepted by SEC EDGAR 03/18/2026 - 06:19 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares. This total includes 150,956 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028, highlighting a multi-year, equity-based incentive structure aligned with her leadership role.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Kim Julie So-Young

Role CEO - Elect

Type	Security	Shares	Price	Value
Holding	American Depositary Shares	--	--	--

Holdings: American Depositary Shares — 324,729 shares (Direct)

Footnotes (1)

1. F1. Includes 150,956 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (70,110 shares), July 1, 2027 (52,218 shares) and July 1, 2028 (28,628 shares).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Julie So-Young Kim’s Form 3 for TAKEDA PHARMACEUTICAL show?

The Form 3 shows CEO-elect Julie So-Young Kim beneficially owns 324,729 American Depositary Shares of Takeda Pharmaceutical. This includes a significant portion in restricted stock units that vest over several future dates.

How many Takeda (TAK) ADS does Julie So-Young Kim beneficially own?

She beneficially owns 324,729 American Depositary Shares of Takeda Pharmaceutical. This figure reflects her total direct position, combining currently held shares and unvested restricted stock units convertible into ADS on future vesting dates.

How many RSUs are included in Julie So-Young Kim’s Takeda (TAK) holdings?

Her position includes 150,956 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share. These RSUs form a substantial part of her overall equity-based compensation with Takeda Pharmaceutical.

What is the vesting schedule for Julie So-Young Kim’s Takeda (TAK) RSUs?

The RSUs vest in three tranches: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028. This creates a long-term incentive aligned with her ongoing service as CEO-elect and future leadership.

Does the Takeda (TAK) Form 3 report any insider share purchases or sales?

The Form 3 does not report purchases or sales; it is an initial ownership filing. It discloses Julie So-Young Kim’s existing beneficial holdings, including both current ADS and unvested RSUs, rather than new market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kim Julie So-Young

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO - Elect

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	324,729(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 150,956 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (70,110 shares), July 1, 2027 (52,218 shares) and July 1, 2028 (28,628 shares).

Remarks:

Exhibit 24 Power of Attorney

	/s/ Max Heuer, by power of attorney, for Julie Kim	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)